Joinn Laboratories and Biomere have joined forces to create a premier global nonclinical contract research organization (CRO) with bi-coastal locations in the U.S. and facilities in China. This merger enhances their scientific portfolio, offering a wide range of preclinical research services from in vitro analyses to discovery toxicology.
Their nonclinical capabilities include pharmacokinetics, lead compound screening, proof of concept, efficacy assessment, and early lead optimization. With a focus on gene therapy, neurology, oncology, and more, Joinn-Biomere is well-equipped to support clients' research needs on a global scale.
Generated from the website